UPDATE: Amylin (AMLN) Rejected $22/Share Bid from Bristol-Myers (BMY)
Tweet
Share
E-mail
Get Alerts AMLN Hot Sheet
Join SI Premium – FREE
(Updated - March 28, 2012 10:00 AM EDT)
Shares of Amylin (Nasdaq: AMLN) have just opened Wednesday's session up a jaw-dropping 50 percent following a Bloomberg report the company rejected a $22 per share bid from Bristol-Myers (NYSE: BMY). Amylin shares closed Tuesday's session at $15.39.
Bloomberg's sources said the offer was sent in a letter to Amylin last month. Bristol-Myers has reportedly not approached Amylin since the company rejected the offer.
UPDATE: an Amylin spokesperson has declined to comment on the reports. Alice Izzo said, "as a matter of company policy, Amylin does not comment on market rumors or speculation."
Amylin shares last traded at $23 even. Bristol-Myers shares are largely unaffected, down 0.06 percent to $33.66.
Shares of Amylin (Nasdaq: AMLN) have just opened Wednesday's session up a jaw-dropping 50 percent following a Bloomberg report the company rejected a $22 per share bid from Bristol-Myers (NYSE: BMY). Amylin shares closed Tuesday's session at $15.39.
Bloomberg's sources said the offer was sent in a letter to Amylin last month. Bristol-Myers has reportedly not approached Amylin since the company rejected the offer.
UPDATE: an Amylin spokesperson has declined to comment on the reports. Alice Izzo said, "as a matter of company policy, Amylin does not comment on market rumors or speculation."
Amylin shares last traded at $23 even. Bristol-Myers shares are largely unaffected, down 0.06 percent to $33.66.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- Vireo Growth completes acquisition of C21 Investments
- MicroCloud Hologram acquires 140,268 MicroStrategy shares via structured note
Create E-mail Alert Related Categories
Mergers and Acquisitions, RumorsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
